Allergan's Juvéderm Vollure XC approved for sale in the U.S.

The U.S. Food and Drug Administration has approved Allergan PLC’s Juvéderm Vollure XC for use correcting moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over 21.
The approval comes after a U.S. trial for the drug that showed that a majority of the subjects, 59 percent, noticed improvements for up to 18 months. Additionally, patients were satisfied during the study; 82 percent claimed to be very satisfied after six months using the product, while 68 percent were satisfied at 18 months.
"The FDA approval of Juvéderm Vollure XC demonstrates Allergan's imperative to develop next-generation HA fillers designed to meet different patient needs," David Nicholson, chief research and development officer at Allergan, said. "This commitment to ongoing scientific research and development is one of the factors that make Juvéderm, the No. 1 selling collection of dermal filler products."
Juvéderm Vollure XC, which was first approved in Europe in 2013, will be available to U.S.-based physicians starting in April. The product will come in gel form to be injected into the facial tissue.